Technical Analysis for CMB - Cambium Bio Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 0.390 | 2.63% | 0.010 |
CMB closed up 2.63 percent on Wednesday, October 2, 2024, on 5.05 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Fell Below 50 DMA | Bearish | 2.63% | |
| Stochastic Sell Signal | Bearish | 2.63% | |
| Narrow Range Bar | Range Contraction | 2.63% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | 1 day ago |
| Gapped Up (Full) | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Rose Above 50 DMA | 1 day ago |
| 10x Volume Pace | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Platform Technology Regenerative Medicine Aging Associated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Platform Technology Regenerative Medicine Aging Associated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.9 |
| 52 Week Low | 0.3 |
| Average Volume | 2,102 |
| 200-Day Moving Average | 0.000 |
| 50-Day Moving Average | 0.381 |
| 20-Day Moving Average | 0.355 |
| 10-Day Moving Average | 0.365 |
| Average True Range | 0.019 |
| RSI (14) | 56.14 |
| ADX | 22.82 |
| +DI | 45.271 |
| -DI | 34.036 |
| Chandelier Exit (Long, 3 ATRs) | 0.338 |
| Chandelier Exit (Short, 3 ATRs) | 0.357 |
| Upper Bollinger Bands | 0.417 |
| Lower Bollinger Band | 0.293 |
| Percent B (%b) | 0.78 |
| BandWidth | 34.949 |
| MACD Line | -0.001 |
| MACD Signal Line | -0.010 |
| MACD Histogram | 0.009 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.390 | ||||
| Resistance 3 (R3) | 0.390 | 0.390 | 0.390 | ||
| Resistance 2 (R2) | 0.390 | 0.390 | 0.390 | 0.390 | |
| Resistance 1 (R1) | 0.390 | 0.390 | 0.390 | 0.390 | 0.390 |
| Pivot Point | 0.390 | 0.390 | 0.390 | 0.390 | 0.390 |
| Support 1 (S1) | 0.390 | 0.390 | 0.390 | 0.390 | 0.390 |
| Support 2 (S2) | 0.390 | 0.390 | 0.390 | 0.390 | |
| Support 3 (S3) | 0.390 | 0.390 | 0.390 | ||
| Support 4 (S4) | 0.390 |
